Cargando…
A Strategy for Selective Deletion of Autoimmunity-Related T Cells by pMHC-Targeted Delivery
Autoimmune diseases such as rheumatoid arthritis are caused by immune system recognition of self-proteins and subsequent production of effector T cells that recognize and attack healthy tissue. Therapies for these diseases typically utilize broad immune suppression, which can be effective, but which...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540115/ https://www.ncbi.nlm.nih.gov/pubmed/34683962 http://dx.doi.org/10.3390/pharmaceutics13101669 |
_version_ | 1784588909442760704 |
---|---|
author | Goldberg, Shalom D. Felix, Nathan McCauley, Michael Eberwine, Ryan Casta, Lou Haskell, Kathleen Lin, Tricia Palovick, Elizabeth Klein, Donna Getts, Lori Getts, Robert Zhou, Mimi Bansal-Pakala, Pratima Dudkin, Vadim |
author_facet | Goldberg, Shalom D. Felix, Nathan McCauley, Michael Eberwine, Ryan Casta, Lou Haskell, Kathleen Lin, Tricia Palovick, Elizabeth Klein, Donna Getts, Lori Getts, Robert Zhou, Mimi Bansal-Pakala, Pratima Dudkin, Vadim |
author_sort | Goldberg, Shalom D. |
collection | PubMed |
description | Autoimmune diseases such as rheumatoid arthritis are caused by immune system recognition of self-proteins and subsequent production of effector T cells that recognize and attack healthy tissue. Therapies for these diseases typically utilize broad immune suppression, which can be effective, but which also come with an elevated risk of susceptibility to infection and cancer. T cell recognition of antigens is driven by binding of T cell receptors to peptides displayed on major histocompatibility complex proteins (MHCs) on the cell surface of antigen-presenting cells. Technology for recombinant production of the extracellular domains of MHC proteins and loading with peptides to produce pMHCs has provided reagents for detection of T cell populations, and with the potential for therapeutic intervention. However, production of pMHCs in large quantities remains a challenge and a translational path needs to be established. Here, we demonstrate a fusion protein strategy enabling large-scale production of pMHCs. A peptide corresponding to amino acids 259–273 of collagen II was fused to the N-terminus of the MHC_II beta chain, and the alpha and beta chains were each fused to human IgG4 Fc domains and co-expressed. A tag was incorporated to enable site-specific conjugation. The cytotoxic drug payload, MMAF, was conjugated to the pMHC and potent, peptide-specific killing of T cells that recognize the collagen pMHC was demonstrated with tetramerized pMHC-MMAF conjugates. Finally, these pMHCs were incorporated into MMAF-loaded 3DNA nanomaterials in order to provide a biocompatible platform. Loading and pMHC density were optimized, and peptide-specific T cell killing was demonstrated. These experiments highlight the potential of a pMHC fusion protein-targeted, drug-loaded nanomaterial approach for selective delivery of therapeutics to disease-relevant T cells and new treatment options for autoimmune disease. |
format | Online Article Text |
id | pubmed-8540115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85401152021-10-24 A Strategy for Selective Deletion of Autoimmunity-Related T Cells by pMHC-Targeted Delivery Goldberg, Shalom D. Felix, Nathan McCauley, Michael Eberwine, Ryan Casta, Lou Haskell, Kathleen Lin, Tricia Palovick, Elizabeth Klein, Donna Getts, Lori Getts, Robert Zhou, Mimi Bansal-Pakala, Pratima Dudkin, Vadim Pharmaceutics Article Autoimmune diseases such as rheumatoid arthritis are caused by immune system recognition of self-proteins and subsequent production of effector T cells that recognize and attack healthy tissue. Therapies for these diseases typically utilize broad immune suppression, which can be effective, but which also come with an elevated risk of susceptibility to infection and cancer. T cell recognition of antigens is driven by binding of T cell receptors to peptides displayed on major histocompatibility complex proteins (MHCs) on the cell surface of antigen-presenting cells. Technology for recombinant production of the extracellular domains of MHC proteins and loading with peptides to produce pMHCs has provided reagents for detection of T cell populations, and with the potential for therapeutic intervention. However, production of pMHCs in large quantities remains a challenge and a translational path needs to be established. Here, we demonstrate a fusion protein strategy enabling large-scale production of pMHCs. A peptide corresponding to amino acids 259–273 of collagen II was fused to the N-terminus of the MHC_II beta chain, and the alpha and beta chains were each fused to human IgG4 Fc domains and co-expressed. A tag was incorporated to enable site-specific conjugation. The cytotoxic drug payload, MMAF, was conjugated to the pMHC and potent, peptide-specific killing of T cells that recognize the collagen pMHC was demonstrated with tetramerized pMHC-MMAF conjugates. Finally, these pMHCs were incorporated into MMAF-loaded 3DNA nanomaterials in order to provide a biocompatible platform. Loading and pMHC density were optimized, and peptide-specific T cell killing was demonstrated. These experiments highlight the potential of a pMHC fusion protein-targeted, drug-loaded nanomaterial approach for selective delivery of therapeutics to disease-relevant T cells and new treatment options for autoimmune disease. MDPI 2021-10-13 /pmc/articles/PMC8540115/ /pubmed/34683962 http://dx.doi.org/10.3390/pharmaceutics13101669 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Goldberg, Shalom D. Felix, Nathan McCauley, Michael Eberwine, Ryan Casta, Lou Haskell, Kathleen Lin, Tricia Palovick, Elizabeth Klein, Donna Getts, Lori Getts, Robert Zhou, Mimi Bansal-Pakala, Pratima Dudkin, Vadim A Strategy for Selective Deletion of Autoimmunity-Related T Cells by pMHC-Targeted Delivery |
title | A Strategy for Selective Deletion of Autoimmunity-Related T Cells by pMHC-Targeted Delivery |
title_full | A Strategy for Selective Deletion of Autoimmunity-Related T Cells by pMHC-Targeted Delivery |
title_fullStr | A Strategy for Selective Deletion of Autoimmunity-Related T Cells by pMHC-Targeted Delivery |
title_full_unstemmed | A Strategy for Selective Deletion of Autoimmunity-Related T Cells by pMHC-Targeted Delivery |
title_short | A Strategy for Selective Deletion of Autoimmunity-Related T Cells by pMHC-Targeted Delivery |
title_sort | strategy for selective deletion of autoimmunity-related t cells by pmhc-targeted delivery |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540115/ https://www.ncbi.nlm.nih.gov/pubmed/34683962 http://dx.doi.org/10.3390/pharmaceutics13101669 |
work_keys_str_mv | AT goldbergshalomd astrategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT felixnathan astrategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT mccauleymichael astrategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT eberwineryan astrategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT castalou astrategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT haskellkathleen astrategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT lintricia astrategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT palovickelizabeth astrategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT kleindonna astrategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT gettslori astrategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT gettsrobert astrategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT zhoumimi astrategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT bansalpakalapratima astrategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT dudkinvadim astrategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT goldbergshalomd strategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT felixnathan strategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT mccauleymichael strategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT eberwineryan strategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT castalou strategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT haskellkathleen strategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT lintricia strategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT palovickelizabeth strategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT kleindonna strategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT gettslori strategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT gettsrobert strategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT zhoumimi strategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT bansalpakalapratima strategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery AT dudkinvadim strategyforselectivedeletionofautoimmunityrelatedtcellsbypmhctargeteddelivery |